Details of a Researcher - Kaseda, Kaoru

Kaseda, Kaoru

写真a

Affiliation: School of Medicine, Department of Surgery (General Thoracic Surgery) (Shinanomachi)

Position: Assistant Professor/Senior Assistant Professor

External Links

Career 【 Display / hide 】

2006.04

-

2008.03

okyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 初期臨床研修医
2008.04

-

2011.03

okyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 後期臨床研修医
2011.04

-

2012.03

Division of Thoracic Surgery, Keio University School of Medicine, 専修医
2012.04

-

2013.03

Pathology Division, Research Center for Innovative Oncology, Department of Thoracic Surgery,National Cancer Center Hospital East, 短期がん専門研修医
2013.04

-

2013.09

Division of Thoracic Surgery, Keio University School of Medicine, 専修医

Academic Degrees 【 Display / hide 】

博士(医学), Keio University, Dissertation, 2016.10

Licenses and Qualifications 【 Display / hide 】

医師免許証, 2006.04
外科専門医, 2011.12
がん治療認定医, 2013.04
呼吸器外科専門医, 2014.01
肺がんCT検診認定機構肺がんCT検診認定医, 2014.10

Research Areas 【 Display / hide 】

Life Science / Tumor diagnostics and therapeutics (Comprehensive Genome Profiling)
Life Science / Respiratory surgery

Research Keywords 【 Display / hide 】

Comprehensive Genome Profiling
Percutaneous cryoablation
Thoracic Surgery
胸部悪性腫瘍の集学的治療

Research Themes 【 Display / hide 】

Lung Cancer,

2011.04

-

Present
がん遺伝子検査,

2011.04

-

Present
Percutaneous cryoablation,

2011.04

-

Present
胸部悪性腫瘍,

2011.04

-

Present

Proposed Theme of Joint Research 【 Display / hide 】

Lung Cancer

Papers 【 Display / hide 】

Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II–III non-small cell lung cancer

Yano K., Kaseda K., Nakamura K., Okubo Y., Masai K., Hishida T., Nukaga S., Ohgino K., Terai H., Yasuda H., Kurebayashi Y., Fukunaga K., Nishihara H., Asakura K.

Scientific Reports 15 ( 1 ) 37477 2025.12

ISSN 2045-2322

　View Summary

The next-generation sequencing (NGS)–based Oncomine Dx Target Test (ODxTT) is the standard tool for guiding postoperative adjuvant therapy in patients with non-small cell lung cancer (NSCLC) in Japan. To advance precision oncology, we evaluated the clinical utility of an in-house comprehensive genomic profiling (CGP) assay, Rapid-Neo, as a complementary approach to ODxTT in surgically resected NSCLC. Patients with pathological stage II–III NSCLC who underwent anatomical surgical resection between December 2019 and May 2024 were included. Resected specimens underwent genomic analysis using both ODxTT and Rapid-Neo CGP. We evaluated the mutational concordance and the frequency of additional actionable alterations identified by CGP. Among 68 eligible patients, driver mutation results were concordant in 64 (94.1%) cases. Crucially, CGP rescued one patient for targeted therapy by detecting an EGFR mutation where ODxTT failed due to insufficient DNA. CGP also identified rare EGFR variants not covered by ODxTT in two cases, although it failed to detect a RET fusion in one patient. Furthermore, CGP revealed additional actionable alterations, such as tumor suppressor gene mutations, in 57 patients (83.8%). Our in-house CGP shows high concordance with ODxTT and serves as a powerful complementary tool. These findings support a strategic testing algorithm where CGP is incorporated for patients with negative or inconclusive ODxTT results, or at the time of recurrence, to maximize opportunities for individualized therapy in resected NSCLC.
- Access to Document (DOI)
Real-World Outcomes of Limited Resection for Tumours Greater Than 20mm in Non-Small Cell Lung Cancer

Suzuki S., Asakura K., Masai K., Kaseda K., Hishida T., Kazama A., Shigenobu T., Hanawa R., Emoto K., Sato Y.

European Journal of Cardio Thoracic Surgery 67 ( 10 ) 2025.10

ISSN 10107940

　View Summary

Sublobar resection is an established surgical option for early-stage non-small cell lung cancer. However, evidence remains limited regarding its use for tumours >20 mm in real-world settings. We evaluated characteristics and outcomes of limited resection in this context and identified predictors of local recurrence. We retrospectively analysed 165 patients with clinical stage I non-small cell lung cancer with tumours >20 mm who underwent limited resection between 2007 and 2017. Clinical, pathological, and radiological data were reviewed. The primary end-point was local recurrence, assessed using competing risk analysis. Overall survival and disease-free survival were estimated using Kaplan-Meier and Cox models. We analysed 165 patients with 13 local recurrence events. Among them, 146 (88.5%) had identifiable reasons for not undergoing lobectomy. Segmentectomy and wedge resection were performed in 59% and 41% of cases, respectively. Lymph node dissection was performed in all segmentectomies and in 20% of wedge resections. The 5-year overall and disease-free survival rates were 64.0% and 62.1%. Local recurrence occurred in 8%, more frequently after wedge resection than segmentectomy (13% vs 4%, P = .04). Solidpredominant tumours with a consolidation-to-tumour ratio greater than 0.5 accounted for 76% and were independently associated with lower disease-free survival (hazard ratio, 2.65; P = .05) and higher local recurrence (hazard ratio: infinite; P < .001). No local recurrence was observed in tumours with a ground-glass opacity-predominant pattern. Limited resection showed acceptable outcomes in lung cancers >20 mm, especially with ground-glass opacity; solidpredominant CT patterns were strongly linked to recurrence.
- Access to Document (DOI)
Lineage-specific transcription factor landscape of thymic neuroendocrine tumors

Omura S., Kurebayashi Y., Hamamoto J., Terai H., Imoto T., Suzuki M., Nakagawa K., Suzuki T., Shigenobu T., Yoshizu A., Maeda C., Kaji M., Okubo Y., Suzuki S., Masai K., Kaseda K., Fukunaga K., Yasuda H., Asakura K.

Lung Cancer 208 108731 2025.10

ISSN 01695002

　View Summary

Introduction: Thymic neuroendocrine tumors (TNETs) are rare malignancies characterized by aggressive clinical behavior and limited therapeutic options. In small cell lung cancer (SCLC), molecular subtypes based on the expression of lineage-defining transcription factors (TFs)—ASCL1, NEUROD1, POU2F3, and YAP1—have been proposed. However, the TF landscape of TNETs remains poorly defined. Given the pathological similarities among neuroendocrine tumors across organs, we aimed to investigate whether the TF-based classification system used in SCLC is applicable to TNETs. Methods: Sixteen pathologically confirmed TNETs—including large cell neuroendocrine carcinoma (LCNEC), thymic small cell carcinoma (TSCC), atypical carcinoid (AC), and typical carcinoid (TC)—were retrospectively analyzed. Immunohistochemistry was performed to evaluate classical neuroendocrine (NE) markers (synaptophysin, chromogranin A, CD56) and TFs (ASCL1, NEUROD1, POU2F3, YAP1). H-scores were calculated, and tumors were categorized according to TFs expression profiles. Results: Synaptophysin was strongly expressed in all cases, while chromogranin A and CD56 showed variable expression, with reduced levels in LCNEC and TSCC. The combined NE score was significantly higher in carcinoid tumors compared to LCNEC and TSCC. For TFs, ASCL1 expression was observed in 93.8 % of cases, whereas NEUROD1 and POU2F3 were rarely or not expressed. YAP1 expression was confined to LCNEC cases, all of which co-expressed ASCL1 and YAP1. Based on H-scores, TNETs were classified into three subgroups: (1) ASCL1-positive/YAP1-negative (n = 12, 75 %), (2) ASCL1/YAP1 double-positive (n = 3, 19 %), and (3) double-negative (n = 1, 6 %). Conclusion: This study reveals molecular heterogeneity among TNETs. Notably, ASCL1 and YAP1 co-expression characterizes all LCNEC cases, making a distinct TF landscape in high-grade TNETs.
- Access to Document (DOI)
Clinical Application of In-House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital.

Takaoka H, Terai H, Nakamura K, Mizuno T, Kawano R, Emoto K, Kurebayashi Y, Takada N, Hamabe K, Horie K, Ogata A, Kinoshita K, Shigematsu L, Ito F, Okada M, Fukushima T, Nukaga S, Tani T, Ohgino K, Kaseda K, Ikemura S, Yasuda H, Asakura K, Okita H, Nishihara H, Fukunaga K

Cancer science 2025.08

ISSN 1347-9032
- Access to Document (DOI)
Clinical Characteristics and Indicators of Spontaneous Hemopneumothorax Comparing With Primary Spontaneous Pneumothorax.

Suzuki M, Kaseda K, Yano K, Omura S, Okubo Y, Masai K, Hishida T, Asakura K

Cureus 17 ( 8 ) e90423 2025.08

ISSN 2168-8184
- Access to Document (DOI)

Papers, etc., Registered in KOARA 【 Display / hide 】

病理病期I期肺腺癌において血管内微小環境が術後再発へ与える影響

Kaseda, Kaoru

(慶應義塾大学大学院医学研究科) 2016
病理病期I期肺腺癌において血管内微小環境が術後再発へ与える影響

Kaseda, Kaoru

(慶應義塾大学大学院医学研究科) 2016
病理病期I期肺腺癌において血管内微小環境が術後再発へ与える影響

Kaseda, Kaoru

(慶應義塾大学大学院医学研究科) 2016
Hemoglobin vesicles ameriolate allograft airway rejection

Kaseda, Kaoru

科学研究費補助金研究成果報告書 2013

Reviews, Commentaries, etc. 【 Display / hide 】

自然気胸の再発は胸郭形態に関連するのか?

政井恭兵, 中山和真, 鈴木嵩弘, 大久保祐, 鈴木繁紀, 加勢田馨, 朝倉啓介

日本気胸・嚢胞性肺疾患学会雑誌 (日本気胸・嚢胞性肺疾患学会) 25 ( 2 ) 84 - 84 2025.08

ISSN 1883-0412
集学的治療により病変を制御した反復性喀血を伴う慢性肺アスペルギルス症の1例

寄森駿, 政井恭兵, 木村征海, 青木優介, 中井猛斗, 中山和真, 櫻田明久, 杉野巧祐, 矢野海斗, 大久保祐, 加勢田馨, 菱田智之, 朝倉啓介

日本胸部外科学会関東甲信越地方会要旨集 (日本胸部外科学会-関東甲信越地方会) ( 198回 ) 19 - 19 2025.06
楔状切除術後の局所再発に対し残肺葉切除を要したEWSR1-CREB1融合遺伝子を有さない原発性肺粘液性肉腫の1例

中山和真, 加勢田馨, 櫻田明久, 杉野功祐, 矢野海斗, 大久保祐, 政井恭兵, 菱田智之, 朝倉啓介, 紅林泰

肺癌 ((NPO)日本肺癌学会) 65 ( 3 ) 233 - 233 2025.06

ISSN 0386-9628
術中3Dナビゲーションを活用した,区域切除の経験

矢野海斗, 朝倉啓介, 山田稔, 木村征海, 寄森駿, 青木優介, 中山和真, 中井猛斗, 櫻田明久, 大久保祐, 政井恭兵, 加勢田馨, 菱田智之

気管支学 ((一社)日本呼吸器内視鏡学会) 47 ( Suppl. ) S161 - S161 2025.05

ISSN 0287-2137
硬性鏡下にdebulkingおよびDumon Yステント留置を施行した原発不明癌による左主気管支狭窄の1例

寄森駿, 大久保祐, 木村征海, 青木優介, 中井猛斗, 中山和真, 櫻田明久, 杉野巧祐, 矢野海斗, 政井恭兵, 加勢田馨, 菱田智之, 朝倉啓介

気管支学 ((一社)日本呼吸器内視鏡学会) 47 ( 3 ) 264 - 264 2025.05

ISSN 0287-2137

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Development of the combination therapy with cryoablation and immune checkpoint inhibitor for lung cancer

2016.04

-

2019.03

Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Kaseda Kaoru, Grant-in-Aid for Young Scientists (B), No Setting

　View Summary

Cryotherapy and cryoimmunotherapy were performed to 1.5cm femoral tumor that originated from Lewis Lung Cancer cell. Histologically, the area of nonviable tumor was significantly increased in size in cryoimmunotherapy group than cryotherapy group (Average: 88% vs 73%). Our data suggest that cryoimmunotherapy is superior than cryotherapy in local control and the most effective route is local administration. On the other hand, there was no difference in the effectiveness of local control between these three immune checkpoint inhibitors.
Hemoglobin vesicles ameriolate allograft airway rejection

2012.04

-

2014.03

Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, KASEDA Kaoru, Grant-in-Aid for Young Scientists (B), No Setting

　View Summary

Acute rejection after lung transplantation is the main risk factor for the development of bronchiolitis obliterans (BO). Hemoglobin-vesicles (HbV) have been developed for use as artificial oxygen carriers and this can provide anti-inflammatory effects and may serve to limit tissue injury in airway transplant. Here, we tested the ability of HbV to prevent airway rejection. Tracheal grafts from BALB/c or C57BL/6 were transplanted to C57BL/6 recipients. Experimental groups were treated with HbV. Histopathological evaluation of luminal obliteration was blindly reviewed. Immunohistochemistry and real-time RT-PCR analyses were performed. Allografts treated with HbV revealed a reduction of thickening in epithelial and subepithelial airway layers at day 7 in orthotopic trachea transplantation model compared with allografts treated with vehicle. There was also a concordant decrease in CD3+ lymphocytes and macrophages in HbV treated allografts.

Courses Taught 【 Display / hide 】

LECTURE SERIES, SURGERY

2025
LECTURE SERIES, SURGERY

2024
LECTURE SERIES, SURGERY

2023
INTRODUCTION TO CLINICAL CLERKSHIPS

2023
CLINICAL TRAINING IN DIAGNOSIS

2023

Memberships in Academic Societies 【 Display / hide 】

日本外科学会

　
日本呼吸器外科学会

　
日本胸部外科学会

　
日本呼吸器内視鏡学会

　
日本肺癌学会

Committee Experiences 【 Display / hide 】

2024.11

-

Present

日本肺癌学会評議員
2021.04

-

Present

日本呼吸器内視鏡学会評議員
2020.10

-

Present

日本呼吸器外科学会評議員